本次股权转让交割手续完成后，公司仍持有中普生物48.99%的股权，中普生物将不再为公司控股子公 司，其财务数据不再纳入公司合并报表范围。 中牧实业股份有限公司关于放弃控股子公司 股权优先购买权的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 一、本次交易情况概述 中牧实业股份有限公司（以下简称"中牧股份"或"公司"）于2025年11月13日、2025年12月1日分别召开 公司第九届董事会2025年第十三次临时会议、2025年第三次临时股东会，审议通过《关于放弃控股子公 司股权优先购买权的议案》，同意公司放弃认购中信农业科技股份有限公司持有的中普生物制药有限公 司（以下简称"中普生物"）4.04%的股权，由普莱柯生物工程股份有限公司（以下简称"普莱柯"）或其 他第三方摘牌受让股权。具体内容详见公司于2025年11月15日披露的《中牧实业股份有限公司关于放弃 控股子公司股权优先购买权的公告》（公告编号：临2025-036）和2025年12月2日披露的《中牧实业股 份有限公司2025年第三次临时股东会决议公告》（公告编号： ...

Core Viewpoint - The company emphasizes its strategic focus on the pet sector, aiming for rapid business development through innovation and investment partnerships [1] Group 1: Strategic Focus - The company is committed to expanding its own brand product market by enhancing product innovation, optimizing channels, and improving service quality [1] - The company is exploring investment collaborations to diversify its pet product offerings, supporting the rapid growth of its pet business segment [1] Group 2: Vaccine Development - The company has no plans to diversify into human vaccines, despite the similarities in immune mechanisms between animal and human vaccines, due to significant differences in regulatory approval, application scenarios, and usage requirements [1]

证券代码：603566 证券简称：普莱柯 公告编号：2025-050 普莱柯生物工程股份有限公司 关于认购中信农业所持中普生物股权的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、本次交易概况 普莱柯生物工程股份有限公司（以下简称"公司"）于 2025 年 12 月 2 日召 开第五届董事会第二十一次会议，审议通过拟认购中信农业科技股份有限公司 （以下简称"中信农业"）所持中普生物制药有限公司（以下简称"中普生物"） 股权的事项；具体详见公司于 2025 年 12 月 3 日在上海证券交易所网站 （www.sse.com.cn）披露的《关于拟认购中信农业所持中普生物股权暨购买资产 的公告》（公告编号：2025-049）。 二、本次交易进展及对公司的影响 近日，公司在完成参与竞拍、确定成为产权交易受让方等相关法定程序后， 于 2025 年 12 月 10 日与中信农业签署《产权交易合同》，并于 2025 年 12 月 15 日取得上海联合产权交易所有限公司出具的《产权交易凭证（A1 类-挂牌类）》， 具体内容如下： ...

普莱柯公告，公司于2025年12月10日与中信农业签署《产权交易合同》，并于2025年12月15日取得上海 联合产权交易所有限公司出具的《产权交易凭证（A1类-挂牌类）》，以1751.43万元受让中普生物制药 有限公司4.04%股权。交易完成后，普莱柯将持有中普生物51.01%股权，中普生物将成为普莱柯控股子 公司。交易资金来源为公司自有资金，不影响现有主营业务正常开展，不会对公司财务状况及经营成果 产生重大影响。 ...

Investment Rating - The report maintains a positive outlook on leading agricultural companies, suggesting investment opportunities in the sector [5]. Core Insights - The agricultural sector has shown resilience, with the industry index outperforming the broader market by 0.4 percentage points during the week of December 8-12, 2025 [13]. - The report highlights significant growth in the pet food segment, with online sales increasing by 27.9% year-on-year during October and November 2025, driven by new consumer brands [34][36]. - The livestock industry is facing challenges, with a 5.5% decrease in the number of pigs marketed in November compared to the previous month, raising concerns about animal disease outbreaks [30]. Summary by Sections Industry Dynamics - The agricultural sector index increased by 0.3%, outperforming the market [13]. - Key stocks such as Zhengbang Technology, Biological Shares, and Luoniushan saw significant gains of 19%, 17%, and 14% respectively [18]. Livestock Industry - In November, the number of pigs marketed decreased by 5.5% month-on-month, with a year-on-year increase of 16.7% [30]. - Prices for live pigs increased by 2.1% week-on-week, while the average weight of marketed pigs decreased by 0.2% [30]. - The utilization rate of fattening barns in 17 provinces dropped by 6.5 percentage points [30]. Poultry Industry - Prices for chicken chicks and broilers increased by 1.4% and 0.8% respectively, amid ongoing global avian influenza outbreaks [37][38]. - The price of chicken products rose by 0.6%, driven by supply constraints and increased export orders [37]. Pet Food Industry - Online sales of pet food reached 8.45 billion yuan, with significant growth from brands like Maifudi and Fresh Lang, which saw increases of 36% and 112.6% respectively [34]. - Chewy reported a 30.9% increase in EBITDA, with active customer numbers growing by 4.9% [35]. Feed Industry - Feed raw material prices showed mixed trends, with soybean meal prices increasing by 1.5% while corn prices slightly decreased [41]. - The price of South American white shrimp increased by 4.3% week-on-week [41]. Animal Health - The veterinary drug price index decreased by 0.2%, with a year-on-year increase of 2.4% [43]. - Merck's imported pet antibiotics were launched on JD Health, marking a significant development in the pet healthcare sector [43].

Core Insights - The animal health sector experienced a decline of 0.31% on December 10, with *ST Lvkang leading the drop [1] - The Shanghai Composite Index closed at 3900.5, down 0.23%, while the Shenzhen Component Index rose by 0.29% to 13316.42 [1] Stock Performance - The following stocks in the animal health sector showed varied performance: - **Biological Shares (600201)**: Closed at 14.53, up 1.18% with a trading volume of 395,300 shares and a turnover of 560 million yuan [1] - **Ruipu Biological (300119)**: Closed at 19.24, up 0.79% with a trading volume of 26,900 shares and a turnover of 51.56 million yuan [1] - **Xianfeng Holdings (002141)**: Closed at 3.82, up 0.53% with a trading volume of 177,700 shares and a turnover of 67.70 million yuan [1] - **Qudongli (920275)**: Closed at 8.71, up 0.23% with a trading volume of 9,815 shares and a turnover of 8.47 million yuan [1] - **Jinhe Biological (002688)**: Closed at 6.05, down 0.17% with a trading volume of 67,700 shares and a turnover of 40.90 million yuan [1] - **Hui Sheng Biological (300871)**: Closed at 19.24, down 0.52% with a trading volume of 23,700 shares and a turnover of 45.48 million yuan [1] - **Dayu Biological (920970)**: Closed at 7.70, down 0.65% with a trading volume of 11,700 shares and a turnover of 892,880 yuan [1] - **KQ Biological (688526)**: Closed at 15.36, down 0.65% with a trading volume of 17,600 shares and a turnover of 26.94 million yuan [1] - **Placo (603566)**: Closed at 12.95, down 0.69% with a trading volume of 27,200 shares and a turnover of 35.32 million yuan [1] - **Shenlian Biological (688098)**: Closed at 8.96, down 1.10% with a trading volume of 31,800 shares and a turnover of 28.66 million yuan [1] Capital Flow - On the same day, the animal health sector saw a net outflow of 13.98 million yuan from institutional investors and 18.34 million yuan from retail investors, while individual investors contributed a net inflow of 32.32 million yuan [3]

Core Viewpoint - The company, Pulaike (603566.SH), emphasizes its research and development capabilities in the veterinary medicine sector, despite concerns about its lag in vaccine development for major diseases like African swine fever compared to competitors. Group 1: R&D Infrastructure - The company has established multiple national and provincial-level innovation platforms, including the National Engineering Research Center for Veterinary Drugs and the National Key Laboratory for Animal Infectious Disease Diagnosis and Vaccine Development [1] - It has built a biosafety level 3 laboratory that is operational and has received approval for activities involving certain pathogenic microorganisms [1] Group 2: Technological Capabilities - The company has developed a comprehensive set of technical platforms over the years, including reverse genetics, prokaryotic and eukaryotic expression technologies, multivalent vaccine technology, high-density fermentation technology, and antigen concentration and purification technology [1] - These platforms enable the company to develop a series of genetically engineered vaccines [1] Group 3: Innovation and Achievements - The company has produced several innovative products that fill gaps in both international and domestic markets, including various inactivated vaccines for poultry and swine [1] - As of now, the company has obtained 81 national new veterinary drug registration certificates, filed over 600 invention patent applications, and received 340 invention patent grants, along with three second-class National Science and Technology Progress Awards [1]

Core Insights - The animal health sector experienced a rise of 1.81% on December 8, with BioShares leading the gains [1] - The Shanghai Composite Index closed at 3924.08, up 0.54%, while the Shenzhen Component Index closed at 13329.99, up 1.39% [1] Stock Performance - BioShares (600201) closed at 14.39, with a significant increase of 7.39% and a trading volume of 717,500 shares, amounting to a turnover of 1.014 billion yuan [1] - Other notable stocks included: - Zhongmu Co. (600195) at 8.09, up 1.25% [1] - Deyu Bio (920970) at 7.88, up 0.90% [1] - Yongshun Bio (920729) at 8.85, up 0.80% [1] - Ruipu Bio (300119) at 19.37, up 0.73% [1] Capital Flow Analysis - The animal health sector saw a net outflow of 27.984 million yuan from institutional investors, while retail investors contributed a net inflow of 4.809 million yuan [2] - The main capital flow for BioShares (600201) showed a net inflow of 26.5384 million yuan from institutional investors, despite a net outflow of 35.9123 million yuan from retail investors [3] - Other stocks like *ST Lvkang (002868) and Huisheng Bio (300871) also experienced varied capital flows, with institutional and retail investors showing different trends [3]

Core Viewpoint - The company, Pulaike, plans to acquire a 4.04% stake in Zhongpu Biological from CITIC Agriculture, which will make Pulaike the controlling shareholder of Zhongpu Biological, a company currently facing continuous losses in the production of foot-and-mouth disease vaccines [1][9]. Company Overview - Zhongpu Biological, formerly known as Baoshan Biological Pharmaceutical Factory, specializes in the research, production, and technical services of foot-and-mouth disease vaccines. It has been in a loss-making state due to declining industry conditions and overcapacity [1][10]. - Pulaike currently holds a 46.97% stake in Zhongpu Biological, while CITIC Agriculture holds 4.04%. After the acquisition, Pulaike's stake will increase to 51.01%, surpassing the current largest shareholder, Zhongmu Co., Ltd. [1][10]. Financial Performance - Zhongpu Biological is projected to generate revenue of 37.01 million yuan in 2024, with a loss of 26.21 million yuan. In the first half of 2025, it is expected to achieve revenue of 18.85 million yuan, with a loss of 18.24 million yuan [2][10]. - Pulaike's revenue for 2024 is expected to decline by 16.77% to 1.043 billion yuan, with a net profit drop of 46.82% to 92.81 million yuan. The gross margin has decreased by 4.32 percentage points, and the net margin has fallen by 13.32 percentage points to 8.9% [4][13]. Industry Challenges - The animal health industry is facing challenges due to a decline in market conditions and overcapacity, with the number of manufacturers producing foot-and-mouth disease vaccines increasing from 7 to 10, leading to an estimated total capacity exceeding 13 billion milliliters per year [2][11]. - The utilization rate of vaccine manufacturers is low, with some companies reporting as low as 20.83% utilization [2][11]. Operational Issues - Pulaike's core business of pig vaccines has been under pressure, with revenue from this segment declining by 22.6% to 336 million yuan in 2024, despite having a gross margin of 83.89% [4][13]. - The company has invested heavily in new production facilities, resulting in a significant increase in depreciation expenses, which rose by 20.65% in 2024 [5][14]. Recent Developments - In the first three quarters of the year, Pulaike's revenue grew by 8.04% to 823 million yuan, and net profit increased by 47.86% to 157 million yuan. However, the growth in net profit is attributed to cost-cutting measures rather than revenue growth [6][15]. - Despite some recovery in new business segments, the overall revenue has started to decline, with a 5.39% drop in the third quarter [7][16]. Accounts Receivable Concerns - As of the end of the third quarter, Pulaike's accounts receivable reached 335 million yuan, accounting for 41% of its revenue, indicating potential cash flow issues [7][16].

Core Viewpoint - The company, Pulaike Biological Engineering Co., Ltd., plans to acquire a 4.04% equity stake in Zhongpu Biological Pharmaceutical Co., Ltd. from CITIC Agriculture Technology Co., Ltd. This acquisition aims to gain control over Zhongpu Biological and improve its operational efficiency and sustainable development capabilities [2][4][5]. Transaction Overview - The transaction does not constitute a related party transaction or a major asset restructuring. It has been approved by the company's board of directors and does not require shareholder approval [3][4]. - The stake being acquired corresponds to an assessed value of 17.5143 million yuan, with the company having a priority purchase right upon the agreement of other shareholders [4][6]. Counterparty Information - CITIC Agriculture is a non-listed joint-stock company with a registered capital of approximately 11.14 billion yuan, established on December 15, 2014. It operates independently from the company in terms of assets and liabilities [5][6]. Target Asset Information - The target asset for this transaction is the 4.04% equity stake in Zhongpu Biological, which is free from any encumbrances or legal disputes [6][7]. - Zhongpu Biological was established in June 2018 with a registered capital of 432.72 million yuan, primarily engaged in the production and sale of veterinary vaccines [7]. Valuation and Pricing - The valuation of the equity stake was conducted by Beijing Zhongqi Hua Asset Appraisal Co., Ltd., using both asset-based and market approaches, with the market approach being favored for its objectivity and relevance to current market conditions [8][9]. Impact on the Company - If the transaction is completed, the company will gain control over Zhongpu Biological, which aligns with its strategic development goals and benefits shareholder interests. The transaction is not expected to lead to management changes or non-operational fund occupation by major shareholders [9].